Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Tappenden

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Pharmacoeconomics|July 26, 2014
Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisalNicholas R Latimer, Christopher Carroll, Ruth Wong, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 25, 2019
Statistical Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Systematic Review of Methodological PapersAbualbishr Alshreef, Nicholas Latimer, Paul Tappenden, et al.
Pharmacoeconomics|December 13, 2016
Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalLesley Uttley, Sophie Whyte, Timothy Gomersall, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 3, 2013
Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosisLesley Uttley, Sue Harnan, Anna Cantrell, et al.
Pharmacoeconomics|December 17, 2013
The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosisPaul Tappenden, Sue Harnan, Lesley Uttley, et al.
Pharmacoeconomics|May 31, 2024
A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health TechnologiesPaul Tappenden, Orla Hardiman, Sun-Hong Kwon, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|August 26, 2004
A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnantMyfanwy Lloyd Jones, Julie Wray, Jeremy Wight, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|August 26, 2004
The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negativeJim Chilcott, Paul Tappenden, Myfanwy Lloyd Jones, et al.
Pharmacoeconomics|March 8, 2020
A Systematic Review of Economic Models Across the Entire Schizophrenia PathwayHuajie Jin, Paul Tappenden, Stewart Robinson, et al.
Pharmacoeconomics|June 29, 2018
Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPaul Tappenden, Christopher Carroll, John Stevens, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Pharmacoeconomics|July 26, 2014
Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisalNicholas R Latimer, Christopher Carroll, Ruth Wong, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 25, 2019
Statistical Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Systematic Review of Methodological PapersAbualbishr Alshreef, Nicholas Latimer, Paul Tappenden, et al.
Pharmacoeconomics|December 13, 2016
Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalLesley Uttley, Sophie Whyte, Timothy Gomersall, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 3, 2013
Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosisLesley Uttley, Sue Harnan, Anna Cantrell, et al.
Pharmacoeconomics|December 17, 2013
The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosisPaul Tappenden, Sue Harnan, Lesley Uttley, et al.
Pharmacoeconomics|May 31, 2024
A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health TechnologiesPaul Tappenden, Orla Hardiman, Sun-Hong Kwon, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|August 26, 2004
A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnantMyfanwy Lloyd Jones, Julie Wray, Jeremy Wight, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|August 26, 2004
The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negativeJim Chilcott, Paul Tappenden, Myfanwy Lloyd Jones, et al.
Pharmacoeconomics|March 8, 2020
A Systematic Review of Economic Models Across the Entire Schizophrenia PathwayHuajie Jin, Paul Tappenden, Stewart Robinson, et al.
Pharmacoeconomics|June 29, 2018
Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPaul Tappenden, Christopher Carroll, John Stevens, et al.
Pageof 9